CorMedix Inc.
| AMEX: CRMD | Healthcare / Biotechnology / USA |
| 3.41 | +0.1200 | +3.65% | Vol 156.37K | 1Y Perf -47.28% |
| Mar 24th, 2023 16:00 DELAYED |
| BID | 3.34 | ASK | 3.50 | ||
| Open | 3.30 | Previous Close | 3.29 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 15.00 | Analyst Rating | Moderate Buy 2.00 | |
| Potential % | 339.88 | Finscreener Ranking | ★★★★+ 56.39 | |
| Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ★★★+ 54.47 | |
| Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | ★★★ 51.73 | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 14.22 | Earnings Rating | Strong Buy | |
| Market Cap | 140.77M | Earnings Date | 30th Mar 2023 | |
| Alpha | 0.03 | Standard Deviation | 0.32 | |
| Beta | 2.13 |
Today's Price Range 3.203.42 | 52W Range 2.658.03 | 5 Year PE Ratio Range -5.70-3.90 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -1.45% | ||
| 1 Month | -14.21% | ||
| 3 Months | -17.03% | ||
| 6 Months | 18.40% | ||
| 1 Year | -47.28% | ||
| 3 Years | 5.25% | ||
| 5 Years | 224.76% | ||
| 10 Years | -22.50% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -77.95 | |||
ROE last 12 Months | -50.90 | |||
ROA (5Y Avg) | -25.14 | |||
ROA last 12 Months | -46.50 | |||
ROC (5Y Avg) | -161.94 | |||
ROC last 12 Months | -46.15 | |||
Return on invested Capital Q | -11.59 | |||
Return on invested Capital Y | -11.63 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 1.80 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -6.10 | ||||
| 3.38 | ||||
| 5.13K | ||||
| - | ||||
| -10.40 | ||||
| -0.61 | ||||
| 3.38 | ||||
| 1.36 | ||||
| 132.14M | ||||
| Forward PE | -3.56 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 11.70 | ||||
| 11.80 | ||||
| 0.01 | ||||
| 0.01 | ||||
| -1 291.00 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 44.30 | ||||
| -32 405.30 | ||||
| -32 316.10 | ||||
| -9 807.40 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 35.71K | ||||
| 0.00 | ||||
| -29.18 | ||||
| -9.90 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2022 | -0.23 | -0.17 | 26.09 |
| Q02 2022 | -0.20 | -0.19 | 5.00 |
| Q01 2022 | -0.23 | -0.18 | 21.74 |
| Q04 2021 | -0.22 | -0.20 | 9.09 |
| Q03 2021 | -0.18 | -0.22 | -22.22 |
| Q02 2021 | -0.18 | -0.12 | 33.33 |
| Q01 2021 | -0.18 | -0.20 | -11.11 |
| Q04 2020 | -0.23 | -0.19 | 17.39 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2022 QR | -0.19 | 17.39 | Positive |
| 12/2022 FY | -0.74 | 10.84 | Positive |
| 3/2023 QR | -0.25 | 0.00 | - |
| 12/2023 FY | -0.96 | -9.09 | Negative |
| Next Report Date | 30th Mar 2023 |
| Estimated EPS Next Report | -0.19 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 156.37K |
| Shares Outstanding | 41.28K |
| Shares Float | 38.74M |
| Trades Count | 1.13K |
| Dollar Volume | 520.48K |
| Avg. Volume | 209.35K |
| Avg. Weekly Volume | 187.94K |
| Avg. Monthly Volume | 209.88K |
| Avg. Quarterly Volume | 230.23K |
CorMedix Inc. (AMEX: CRMD) stock closed at 3.41 per share at the end of the most recent trading day (a 3.65% change compared to the prior day closing price) with a volume of 156.37K shares and market capitalization of 140.77M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 30 people. CorMedix Inc. CEO is Khoso Baluch.
The one-year performance of CorMedix Inc. stock is -47.28%, while year-to-date (YTD) performance is -19.19%. CRMD stock has a five-year performance of 224.76%. Its 52-week range is between 2.645 and 8.025, which gives CRMD stock a 52-week price range ratio of 14.22%
CorMedix Inc. currently has a PE ratio of -6.10, a price-to-book (PB) ratio of 3.38, a price-to-sale (PS) ratio of 5 133.39, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -46.50%, a ROC of -46.15% and a ROE of -50.90%. The company’s profit margin is -%, its EBITDA margin is -32 316.10%, and its revenue ttm is $35.71 Thousand , which makes it $0.00 revenue per share.
Of the last four earnings reports from CorMedix Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.19 for the next earnings report. CorMedix Inc.’s next earnings report date is 30th Mar 2023.
The consensus rating of Wall Street analysts for CorMedix Inc. is Moderate Buy (2), with a target price of $15, which is +339.88% compared to the current price. The earnings rating for CorMedix Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CorMedix Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CorMedix Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 29.34, ATR14 : 0.23, CCI20 : -100.08, Chaikin Money Flow : -0.37, MACD : -0.23, Money Flow Index : 18.21, ROC : -13.23, RSI : 38.55, STOCH (14,3) : 26.25, STOCH RSI : 0.98, UO : 39.32, Williams %R : -73.75), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CorMedix Inc. in the last 12-months were: Joseph Todisco (Buy at a value of $128 624), Myron Kaplan (Buy at a value of $18 900)
CorMedix Inc.
Cormedix Inc is a biopharmaceutical company which focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It has in-licensed to develop and commercialize Neutrolin, which is a novel anti-infective solution or the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as dialysis, critical/intensive care, and oncology. The Neutrolin product is designed to target unmet medical need.
CEO: Khoso Baluch
Telephone: +1 908 517-9500
Address: 400 Connell Drive, Berkeley Heights 07922, NJ, US
Number of employees: 30
